Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit!

If you are interested in the 2026 event, please get in touch at info@hansonwade.com

Leverage Industry Case Studies in Robust Model Validation for Regulatory Use & Establish Reproducibility to Optimize Complex In Vitro Models for Discovery, Translational, Efficacy & Safety Studies

2025 EVENT GUIDE

WELCOME TO THE 3D TISSUE MODELS SUMMIT!

BULLETPROOF VALIDATION, ENHANCE REPRODUCIBILITY, SECURE REGULATORY SUPPORT

Following the FDA’s introduction of the Modernization Act 3.0 and the latest guidance on new approach methods (NAMs), GSK developing a new lung organoid model to empower pulmonary fibrosis research, and Merck acquiring HUB Organoids to enable more effective drug development and reduce reliance on animal testing, it’s an exciting time for pharma and biotech to leverage complex in vitro models in drug discovery and development.

Despite this growth, challenges persist in standardizing protocols for model validation, safeguarding model reproducibility while ensuring scalability, and understanding what data regulators will accept.

Built by biopharma-for-biopharma, the 10th 3D Tissue Models Summit returned to unite ‘front-line’ experts to share practical case studies on validating, improving reproducibility, and interrogating regulatory requirements for complex in vitro models in drug discovery and development.

The only intimate, industry-focussed forum to stay abreast on how to confidently harness various complex in vitro models to transform your own discovery and development workflows and empower clinical translatability.

2025 WORLD-CLASS SPEAKER FACULTY INCLUDED:

Jason Ekert

Head of Neuromuscular Translational Biology

UCB Pharma

Julie Harney

Senior Principal Scientist

Pfizer

Julien Roth

Senior Scientist

Genentech

Muriel Lize

Scientific Expert – Immunology & Respiratory Discovery Sciences

Boehringer Ingelheim

Philip Hewitt

Global Head of Early Investigative Toxicology

Merck

Soumya Mitra

Senior Principal Research Scientist

Abbvie

COMPANIES IN THE ROOM IN 2025 INCLUDED:

WHAT WAS NEW FOR 2025?

Identified practical use cases of MPS with NCATS/NIH to qualify their use in submissions and facilitate regulatory approval
Optimized and validate complex in vitro models of the CNS with Genentech to enhance neurotoxicity predictions and empower safer drug development
Discovered protocols to validate and ensure reproducibility of organoids with Pfizer to de-risk therapeutic development before the move to the clinic
Harnessed bioconvergence using validated MPS data with Merck to transform drug discovery and reduce reliance on animal testing
Explored elevated strategies to apply reverse translation with Boehringer Ingelheim to better validate complex in vitro models

WHAT THEY THOUGHT:

“I really enjoyed the 3D summit, where experts and partners were focused on the similar topics therefore, it was very easy to form network, collaboration with colleagues with the same interests.”

“Not a large size of the meeting allowed for better engagement.”

“I really liked how there were many opportunities to network during the conference. I was able to make a lot of great connections and brainstorm new ideas with fellow peers.”

“I enjoyed the small intimate environment and the good science that was presented.”

“Having participants from government, pharma and vendors coming together to share insight and feedback help us understand the challenges faced by all and come up with ways to overcome them.”